Cargando…
Double Jeopardy: Will the new trials tell us how to manage patients with atrial fibrillation and coronary artery disease?
Autores principales: | Wakili, Reza, Riesinger, Lisa, Fender, Anke C., Dobrev, Dobromir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510696/ https://www.ncbi.nlm.nih.gov/pubmed/31111088 http://dx.doi.org/10.1016/j.ijcha.2019.100369 |
Ejemplares similares
-
The temporal context of oral anticoagulation outcome in atrial fibrillation
por: Fender, Anke C., et al.
Publicado: (2022) -
Recent highlights on thrombosis and hemostasis from the International Journal of Cardiology: Heart & Vasculature
por: Fender, Anke C., et al.
Publicado: (2022) -
Stroke prevention of atrial fibrillation: Improving geographic under-use of contemporary antithrombotic approaches remains a challenge
por: Riesinger, L., et al.
Publicado: (2021) -
Anticoagulation in difficult settings RELOADed: Evidence for applicability of direct oral anticoagulants in patients with atrial fibrillation, renal impairment and cancer
por: Fender, Anke C., et al.
Publicado: (2019) -
Breaking bad: Higher risk of osteoporosis with vitamin K antagonists compared to direct oral anticoagulants in patients with atrial fibrillation
por: Fender, Anke C., et al.
Publicado: (2020)